Ackerson, Bradley K

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · The Lancet

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 1,167

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 541

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Tseng, H. F., Ackerson, B. K., Bruxvoort, K. J., Sy, L. S., Tubert, J. E., Lee, G. S., Ku, J. H., Florea, A., Luo, Y., Qiu, S., et al. (2023) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 105

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Ackerson, B. K., Takhar, H., Ogun, O. A., Simmons, S., Zamparo, J. M., et al. (2022) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 66

Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M. (2023) · The Lancet Respiratory Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 36